Sustainability Declaration

The report presents BioInvent's sustainability declaration for its fully integrated cancer-immunotherapy organization, covering governance, value-chain, workforce and environmental topics. It describes a double materiality assessment and prioritizes SDGs 3, 9, 10 and 17. The declaration reports 2024 gross GHG emissions of 491,958 tCO2e, including Scope 1 of 0, Scope 2 of 16.47 and Scope 3 of 475.489 tCO2e, alongside total energy use of approximately 1,339 MWh and waste of 15 tonnes. It also reports 126 employees at year-end and 40% women on the board, and states that ISO 26000 verification was achieved.